Melatonin and omentin: Influence factors in the obstructive sleep apnoea syndrome?

Journal of Physiology and Pharmacology

Volumn 64, Issue 3, 2013, Pages

  Zirlik, Sabine ^a   Hildner, K M ^a   Targosz, A ^c   Neurath, M F ^a   Fuchs, F S ^a   Brzozowski, T ^c   Konturek, P C ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Adipokines; Melatonin; Obstructive sleep apnoea syndrome; Omentin 1 positive airway pressure; Sleep wake rhythm

Indexed keywords

ADIPOCYTOKINE; MELATONIN; OMENTIN 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MALE; PATHOGENESIS; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SLEEP DISORDERED BREATHING; TREATMENT DURATION; BLOOD; BODY MASS; CIRCADIAN RHYTHM; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; RADIOIMMUNOASSAY; SEVERITY OF ILLNESS INDEX; COMPLICATION; SLEEP APNEA, OBSTRUCTIVE;

BIOLOGICAL MARKERS; BODY MASS INDEX; CIRCADIAN RHYTHM; CONTINUOUS POSITIVE AIRWAY PRESSURE; CYTOKINES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MELATONIN; MIDDLE AGED; OBESITY; OVERWEIGHT; RADIOIMMUNOASSAY; SEVERITY OF ILLNESS INDEX; SLEEP APNEA, OBSTRUCTIVE;

EID: 84881608080     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Ulfberg J, Micic S, Strom J. Afternoon serum-melatonin in sleep disordered breathing. J Intern Med 1998; 244: 163-168.
2. Azagra-Calero E, Espinar-Escalona E, Barrera-Mora JM, Llamas-Carreras JM, Solano-Reina E. Obstructive sleep apnea syndrome (OSAS). Review of the literature. Med Oral Patol Oral Cir Bucal 2012; 17: e925-e929.
3. Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010; 7: 677-685.
4. Hecht L, Mohler R, Meyer G. Effects of CPAP-respiration on markers of glucose metabolism in patients with obstructive sleep apnoea syndrome: a systematic review and meta-analysis. Ger Med Sci 2011; epub 2011 Aug 8. doi: 10.3205/000143.
5. Mahboub B, Afzal S, Alhariri H, Alzaabi A, Vats M, Soans A. Prevalence of symptoms and risk of sleep apnea in Dubai, UAE. Int J Gen Med 2013; 6: 109-114.
6. Tufik S, Santos-Silva R, Taddei JA, Bittencourt LR. Obstructive sleep apnea syndrome in the Sao Paulo Epidemiologic Sleep Study. Sleep Med 2010; 11: 441-446.
7. Franco CM, Lima AM, Ataide L Jr., et al. Obstructive sleep apnea severity correlates with cellular and plasma oxidative stress parameters and affective symptoms. J Mol Neurosci 2012; 47: 300-310.
8. Hernandez C, Abreu J, Abreu P, Castro A, Jimenez A. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J 2007; 30: 496-500.
9. Alves ED, Ackel-D'Elia C, Luz GP, et al. Does physical exercise reduce excessive daytime sleepiness by improving inflammatory profiles in obstructive sleep apnea patients? Sleep Breath 2013; 17: 505-510.
10. Dempsey JA, Veasey SC, Morgan BJ, ÓDonnell CP. Pathophysiology of sleep apnea. Physiol Rev 2010; 90: 47-112.
11. Bulcun E, Ekici M, Ekici A. Disorders of glucose metabolism and insulin resistance in patients with obstructive sleep apnoea syndrome. Int J Clin Pract 2012; 66: 91-97.
12. Tamura A, Kawano Y, Watanabe T, Kadota J. Relationship between the severity of obstructive sleep apnea and impaired glucose metabolism in patients with obstructive sleep apnea. Respir Med 2008; 102: 1412-1416.
13. Lavie P, Lavie L, Herer P. All-cause mortality in males with sleep apnoea syndrome: declining mortality rates with age. Eur Respir J 2005; 25: 514-520.
14. Lacasse Y, Godbout C, Series F. Health-related quality of life in obstructive sleep apnoea. Eur Respir J 2002; 19: 499-503.
15. Quercioli A, Mach F, Montecucco F. Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath 2010; 14: 261-269.
16. Salvador J, Iriarte J, Silva C, Gomez Ambrosi J, Diez Caballero A, Fruhbeck G. The obstructive sleep apnoea syndrome in obesity: a conspirator in the shadow. Rev Med Univ Navarra 2004; 48: 55-62.
17. Nerfeldt P, Nilsson BY, Mayor L, Udden J, Friberg D. A two-year weight reduction program in obese sleep apnea patients. J Clin Sleep Med 2010; 6: 479-486.
18. Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012; 4: 37.
19. Auguet T, Quintero Y, Riesco D, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011; 12: 60.
20. Kalisz M, Baranowska B, Bik W. Do novel adipokines play a causative or only modulating role in the pathogenesis of obesity and metabolic disorders? Neuro Endocrinol Lett 2012; 33: 11-55.
21. Castan-Laurell I, Dray C, Attane C, Duparc T, Knauf C, Valet P. Apelin, diabetes, and obesity. Endocrine 2011; 40: 1-9.
22. Declercq V, Enns J, Yeganeh A, Taylor C, Zahradka P. Modulation of cardiovascular function by adipokines. Cardiovasc Hematol Disord Drug Targets 2012; 13: 59-72.
23. Feng X, Li P, Zhou C, Jia X, Kang J. Elevated levels of serum chemerin in patients with obstructive sleep apnea syndrome. Biomarkers 2012; 17: 248-253.
24. Zirlik S, Hauck T, Fuchs FS, Neurath MF, Konturek PC, Harsch IA. Leptin, obestatin and apelin levels in patients with obstructive sleep apnoea syndrome. Med Sci Monit 2011; 17: CR159-CR164.
25. Trakada G, Steiropoulos P, Nena E, et al. Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome. Sleep Breath 2009; 13: 349-355.
26. Sanchez-de-la-Torre M, Mediano O, Barcelo A, et al. The influence of obesity and obstructive sleep apnea on metabolic hormones. Sleep Breath 2012; 16: 649-656.
27. Zhou JY, Chan L, Zhou SW. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol 2012; epub. Jun 22.
28. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2012; 20: 143-148.
29. Ismail SA, Mohamed SA. Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. Br J Dermatol 2012; 167: 436-439.
30. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-E1261.
31. Shibata R, Ouchi N, Kikuchi R, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011; 219: 811-814.
32. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661.
33. Brunetti L, Nisio C, Recinella L, et al. Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat. Peptides 2011; 32: 1866-1871.
34. Choi JH, Rhee EJ, Kim KH, Woo HY, Lee WY, Sung KC. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol 2011; 165: 789-796.
35. El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med 2011; 28: 1194-1200.
36. Yoo HJ, Hwang SY, Hong HC, et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol 2011; 10: 103.
37. Shang FJ, Wang JP, Liu XT, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 2011; 16: 657-662.
38. Cantarini L, Simonini G, Fioravanti A, et al. Circulating levels of the adipokines vaspin and omentin in patients with juvenile idiopathic arthritis, and relation to disease activity. Clin Exp Rheumatol 2011; 29: 1044-1048.
39. Alcelik A, Tosun M, Ozlu MF, et al. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res 2012; 35: 511-516.
40. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012; 686: 116-123.
41. Northcott JM, Yeganeh A, Taylor CG, Zahradka P, Wigle JT. Adipokines and the cardiovascular system: mechanisms mediating health and disease. Can J Physiol Pharmacol 2012; 90: 1029-1059.
42. Wang Q, Feng X, Zhou C, Li P, Kang J. Decreased levels of serum omentin-1 in patients with obstructive sleep apnoea syndrome. Ann Clin Biochem 2013; 50: 230-235.
43. Konturek PC, Brzozowski T, Konturek SJ. Gut clock: implication of circadian rhythms in the gastrointestinal tract. J Physiol Pharmacol 2011; 62: 139-150.
44. Stehle JH, Saade A, Rawashdeh O, et al., A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011; 51: 17-43.
45. Bubenik GA, Konturek SJ. Melatonin and aging: prospects for human treatment. J Physiol Pharmacol 2011; 62: 13-19.
46. Rastmanesh R, de Bruin PF. Potential of melatonin for the treatment or prevention of obesity: an urgent need to include weight reduction as a secondary outcome in clinical trials of melatonin in obese patients with sleep disorders. Contemp Clin Trials 2012; 33: 574-575.
47. Anton-Tay F, Diaz JL, Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci I 1971; 10: 841-850.
48. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 2008; 5: 173-178.
49. Avlonitou E, Kapsimalis F, Varouchakis G, Vardavas Cl, Behrakis P. Adherence to CPAP therapy improves quality of life and reduces symptoms among obstructive sleep apnea syndrome patients. Sleep Breath 2012; 16: 563-569.
50. Tasali E, Chapotot F, Leproult R, Whitmore H, Ehrmann DA. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: 365-374.
51. Campos-Rodriguez F, Pena-Grinan N, Reyes-Nunez N, et al. Mortality in obstructive sleep apnea-hypopnea patients treated with positive airway pressure. Chest 2005; 128: 624-633.
52. Cichoz-Lach H, Celinski K, Konturek PC, Konturek SJ, Slomka M. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis. J Physiol Pharmacol 2010; 61: 577-580.
53. Indications and standards for use of nasal continuous positive airway pressure (CPAP) in sleep apnea syndromes. American Thoracic Society. Official statement adopted March 1944. Am J Respir Crit Care Med 1994; 150: 1738-1745.
54. Penzel T, Hajak G, Hoffmann RM, et al. Empfehlungen zur Durchführung und Auswertung polygraphischer Ableitungen im diagnostischen Schlaflabor. EEG-EMG 1993; 24: 65-70.
55. Ficker JH, Wiest GH, Lehnert G, Wiest B, Hahn EG. Evaluation of an auto-CPAP device for treatment of obstructive sleep apnoea. Thorax 1998; 53: 643-648.
56. Rechtschaffen A, Kahles A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Public Health Service, US Government Printing Office 1968.
57. Bonnet M, Carley D, Carskadon M, et al. EEG arousals: scoring rules and examples. Sleep 1992; 15: 174-184.
58. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012; 49: 89-96.
59. Turkay C, Ozol D, Kasapoglu B, Kirbas I, Yildirim Z, Yigitiglu R. Influence of obstructive sleep apnea on fatty liver disease: role of chronic intermittent hypoxia. Respir Care 2012; 57: 244-249.
60. Musso G, Olivetti C, Cassader M, Gambino R. Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: emerging evidence and mechanisms. Semin Liver Dis 2012; 32: 49-64.
61. Yilmaz Y, Yonal O, Kurt R, et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011; 46: 91-97.
62. Moreno-Navarrete JM, Catalan V, Ortega F, et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010; 7: 27.
63. Shibata R, Ouchi N, Kikuchi R, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011; 219: 811-814.
64. Brzecka A, Piesiak P, Zareba-Bogdal E, Zierkiewicz G, Plamieniak Z. Rhythm of melatonin excretion in obstructive sleep apnea syndrome (in Polish). Pneumonol Alergol Pol 2001; 69: 650-654.
65. Wikner J, Svanborg E, Wetterberg L, Rojdmark S. Melatonin secretion and excretion in patients with obstructive sleep apnea syndrome. Sleep 1997; 20: 1002-1007.
66. Akbarzadeh S, Nabipour I, Assadi M, et al. The normoglycemic first-degree relatives of patients with type 2 diabetes mellitus have low circulating omentin-1 and adiponectin levels. Cytokine 2012; 58: 295-299.
67. Fazeli MS, Dashti H, Akbarzadeh S, Assadi M, et al. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine 2013; 62: 81-85.
68. Zhong X, Zhang H, Tan H, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin 2011; 32: 873-878.
69. Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 257-263.
70. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity 2011; 19: 1552-1559.
71. Lewandowski K, Nadel I, Lewinski A, et al. Positive correlation between serum omentin and thrombospondin-1 in gestational diabetes despite lack of correlation with insulin resistance indices. Ginekol Pol 2010; 81: 907-912.